Itch with bleeding, altered bowel habit, anaemia or a mass Suspected cancer Anal itch itself is not an NG12 trigger — the accompanying symptom is. Offer quantitative FIT per NICE NG12 (unexplained change in bowel habit, iron-deficiency anaemia, abdominal mass, rectal bleeding in the relevant age/symptom groups); FIT ≥10 µg Hb/g → colorectal suspected cancer pathway. A rectal mass, or unexplained anal mass or ulceration, is referred without FIT; a low, unavailable or unreturned FIT must not delay referral if concern remains. Do not attribute bleeding to haemorrhoids without examination.
Persistent asymmetric, scaly, crusted, pigmented, indurated or ulcerated plaque Consider extramammary Paget disease (rare), anal intraepithelial neoplasia/Bowen disease or invasive malignancy, especially if treatment-resistant → urgent assessment and biopsy via the clinically appropriate service (dermatology, colorectal or anogenital neoplasia pathway).
Generalised itch + jaundice Cholestatic liver disease (PBC, PSC, bile duct obstruction). New jaundice → same-day clinical assessment with LFTs and bilirubin; aged 40 and over → suspected cancer pathway referral for pancreatic cancer (NICE NG12). LFTs + bilirubin — reserved for jaundice, cholestatic symptoms or significant generalised itch, not uncomplicated anal itch.
Generalised itch + systemic symptoms Lymphoma (Hodgkin's — severe nocturnal itch), CKD (uraemic pruritus), polycythaemia vera (aquagenic pruritus after bathing), thyroid disease. FBC + U&E + TFTs + LFTs.
Perianal itch in child + safeguarding Consider threadworm, irritant dermatitis, eczema, psoriasis, lichen sclerosus and infection as well as safeguarding. Warts, genital lesions, trauma, bleeding, disclosure, STI or concerning context → same-day discussion with the safeguarding lead or on-call paediatrician, and referral to children's social care under local safeguarding protocols. Lichen sclerosus does not exclude abuse; warts alone do not establish it.
New perianal warts (condylomata acuminata) HPV. Sexual-health assessment for new, multiple, recurrent, atypical or symptomatic warts or relevant exposure; HIV/STI testing by risk. HPV typing is not routinely required. Biopsy if atypical, indurated, ulcerated, pigmented, bleeding or treatment-resistant. HIV-positive and other high-risk groups may need specialist assessment.